Frontiers in Cardiovascular Medicine

MARCH 30, 2025

The independent risk factors for mortality included left ventricular ejection fraction (LVEF), pulmonary hypertension, and low-density lipoprotein (LDL) levels (P<0.05). LVEF, pulmonary hypertension, and LDL levels are critical prognostic factors, offering insights for risk assessment and management in affected children.

Risk Factors 52

Risk Factors Pediatrics Cardiomyopathy Pulmonary 52

Hypertension Journal

AUGUST 5, 2024

Hypertension, Ahead of Print. Hypertension is a leading risk factor for cardiovascular morbidity and mortality. Most but not all of the new generation of trials reached their primary end point, demonstrating modest efficacy of renal denervation in lowering blood pressure across a spectrum of hypertension, from mild to truly resistant.

Hypertension 77

Hypertension Blood Pressure Pharmacology Risk Factors 77

DAIC

MAY 6, 2024

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that I.V. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

Preserved Ejection Fraction 105

Preserved Ejection Fraction Heart Failure Pulmonary Hypertension 105

DAIC

JANUARY 19, 2024

milla1cf Fri, 01/19/2024 - 10:55 January 19, 2024 — Orchestra BioMed , a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the first patient was randomized in the BACKBEAT pivotal study in late December 2023. Orchestra BioMed and Medtronic, Inc. Kowal, M.D.,

Pacemaker 105

Pacemaker Hypertension Blood Pressure Kidney Disease 105

Dr. Paddy Barrett

NOVEMBER 29, 2024

1 The global epidemiology of hypertension. Hypertension. Hypertension. 6 Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker: A Secondary Analysis of a Randomized Clinical Trial. Get 30% off with discount code HEART30. Nat Rev Nephrol. N Engl J Med.

Blood Pressure 87

Blood Pressure ACE Inhibitor Hypertension Cardiovascular Disease 87

Cardiovascular Diabetology

AUGUST 11, 2024

We evaluated the prevalence of “heart stress” (HS) based on NT-proBNP cut-points proposed by the 2023 Consensus of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in asymptomati.

Blood Pressure 111

Blood Pressure Heart Failure Hypertension Diabetes 111

Dr. S. Venkatesan MD

JANUARY 25, 2024

Here is a pleasant surprise, a collectors issue of NEJM year book 2023, is made available free (even for a non subscribers in its website).It Baxdrostat, an Aldosterone synthase antagonist for treatment-resistant Hypertension, appears promising (BrigHTN). Notable articles of 2023 from NEJM.

Research 52

Research Article Document Public Health 52

Cardiometabolic Health Congress

NOVEMBER 16, 2023

2-5, 2023, to gain perspective on the latest advances in the management of glomerular disease. Kidney Week 2023 not only served as a platform for the latest news and updates in the field but also marked the final meeting of the year for practitioners in the specialty of nephrology.

Kidney Disease 52

Kidney Disease Blood Pressure Diabetes Hospital 52

Open Heart

APRIL 15, 2024

Background and aims Hypertension is a leading risk factor for cardiovascular disease. This study aimed to identify codelists used to define hypertension in studies that use EHRs and generate recommended codelists to support reproducibility and consistency. EHRs can be used for epidemiological research.

Hypertension 52

Hypertension Research Risk Factors Cardiovascular Disease 52

Open Heart

AUGUST 30, 2024

Objective To describe the impact of the pandemic on blood pressure screening and hypertension management based on a national quality of care scheme (Quality and Outcomes Framework, QOF) across key demographic, regional and clinical subgroups. million NHS patients registered at general practices (March 2019 to March 2023).

COVID-19 52

COVID-19 Blood Pressure Hypertension Outcomes 52

Frontiers in Cardiovascular Medicine

DECEMBER 14, 2023

Background Pulmonary hypertension (PH) is linked to higher rates of morbidity and mortality worldwide. Methods In the retrospective study, patients admitted to our hospital between January 2022 and April 2023 were classified into PH and control groups using ePASP and compared with acoustic cardiographic parameters.

Pulmonary 64

Pulmonary Hypertension Hospital Outcomes 64

Wellnest

DECEMBER 18, 2023

In November 2023, the FDA approved 2 new RDN therapies: Paradise by Recor Medical and Symplicity Spyral by Medtronic. But what is resistant hypertension, and why does it require renal denervation? Hypertension vs Resistant Hypertension Normal blood pressure is generally around 120/80 mm Hg.

Hypertension 52

Hypertension Blood Pressure Ablation Reimbursement 52

Hypertension Journal

OCTOBER 13, 2023

Hypertension, Volume 80, Issue 12 , Page 2501-2505, December 1, 2023.

Hypertension 40

Hypertension 40

Hypertension Journal

SEPTEMBER 28, 2023

Hypertension, Volume 80, Issue 12 , Page 2506-2514, December 1, 2023. billion people worldwide suffer from arterial hypertension, a significant risk factor for cardiovascular disease which is now the leading cause of death.

Hypertension 40

Hypertension Blood Pressure Risk Factors Cardiovascular Disease 40

Hypertension Journal

OCTOBER 6, 2023

Hypertension, Volume 80, Issue 12 , Page 2650-2664, December 1, 2023. BACKGROUND:Inflammation plays a critical role in the development of hypertension and vascular remodeling. RvE1/ChemR23 may be a potential therapeutic target for hypertension.

Hypertension 40

Hypertension Aortic Blood Pressure 40

Hypertension Journal

NOVEMBER 14, 2023

Hypertension, Volume 80, Issue 12 , Page 2544-2546, December 1, 2023.

Hypertension 40

Hypertension 40

DAIC

NOVEMBER 8, 2024

Additional details and the notice can be found here: [link] The Paradise uRDN system is designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension.

CMS 40

CMS Ultrasound Blood Pressure Reimbursement 40

Frontiers in Cardiovascular Medicine

FEBRUARY 28, 2024

Background As a therapy to prevent and treat essential hypertension (EH), traditional Chinese exercises (TCEs) were widely used in clinical practice. However, there is a lack of strictly comparison of the antihypertensive efficacy of different TCEs, which not conducive to the selection of the best and most optimal treatment. and Stata 17.0.

Exercise 59

Exercise Blood Pressure Hypertension Outcomes 59

Cardiometabolic Health Congress

JANUARY 15, 2025

The Global Burden of Disease data (2023) highlights a grim reality: while high-income countries have seen some success in managing CVD, LMICs now account for most CVD-related deaths. This shift results from an epidemiologic transition: as infectious diseases decline, chronic conditions like atherosclerosis dominate.

Atherosclerosis 59

Atherosclerosis Plaque Myocardial Infarction Risk Factors 59

Dr. Smith's ECG Blog

JUNE 5, 2024

He has a medical hx notable for hypertension, hyperlipidemia and previous tobacco use disorder. This combination is often extremely effective for maintaining good longterm outcome ( Lanza and Shimokawa — Eur Cardiol 18: e38, 2023 ). Written by Magnus Nossen The patient in todays case is a 50 year old male. The below ECG was recorded.

Chest Pain 122

Chest Pain Blog Cardiac Arrest Cardiomyopathy 122

Hypertension Journal

OCTOBER 11, 2023

Hypertension, Volume 80, Issue 12 , Page 2591-2600, December 1, 2023. RESULTS:The median age of the patients was 76 years, and 54.9% were women. The total AHT incidence was 70 cases per 100 000 admission year. Urgent dialysis rates increased from 1.52% (95% CI, 1.12–2.06) 2.06) to 2.60% (2.17–3.1;

Hypertension 40

Hypertension Kidney Disease Heart Failure Risk Factors 40

Dr. Malcolm Kendrick

DECEMBER 10, 2023

10th December 2023 A very important study – please watch Very high low density lipoprotein levels with no impact on plaque progression I interrupt my series on what is wrong with the health service to bring you breaking news. They were all healthy with none of them having diabetes, or hypertension, meaning that they were well matched.

Plaque 144

Plaque Cholesterol Diet Diabetes 144

Hypertension Journal

OCTOBER 13, 2023

Hypertension, Volume 80, Issue 12 , Page 2581-2590, December 1, 2023. BACKGROUND:This study aimed to develop a risk-scoring model for hypertension among Africans.METHODS:In this study, 4413 stroke-free controls were used to develop the risk-scoring model for hypertension. for the training set and 64.6% (95% CI, 61.0–68.0)

Hypertension 40

Hypertension BMI Risk Factors Education 40

Stroke Journal

JANUARY 30, 2025

Our purpose was to evaluate the 10-year trends in the last known well to arrival (LKWA) time in AIS patients and assess disparities.Methods:A retrospective study of consecutive AIS patients admitted to a large integrated healthcare system was performed over a 10-year period from 2014-2023. 1.41]), hypertension (1.15 [1.05-1.25]),

Medicaid 40

Medicaid Strokes Stroke Outcomes 40

Dr. Smith's ECG Blog

JANUARY 20, 2024

Written by Pendell Meyers A man in his late 30s with history of hypertension, tobacco use, and obesity presented to the Emergency Department for acute chest pain which started approximately 3 hours prior to arrival, in the setting of a very stressful situation. Vitals were within normal limits except some hypertension. Which is true.

Chest Pain 121

Chest Pain STEMI Hypertension Blog 121

Stroke Journal

NOVEMBER 26, 2023

Stroke, Volume 54, Issue 12 , Page 3141-3152, December 1, 2023. This induction of SA, which, in turn, will independently exacerbate hypertension and neural inflammation, increases the rate of vascular dementia. BACKGROUND:Sleep apnea (SA) is a major threat to physical health and carries a significant economic burden.

Hypertension 40

Hypertension Dementia Atherosclerosis Strokes 40

DAIC

MARCH 21, 2024

with SmartAssist ; Impella LD Product Codes: See Recall Database Entry Distribution Dates: October 10, 2021 to October 10, 2023 Devices Recalled in the U.S.: Recalled Product US Available Product Names: Impella 2.5; Impella CP; Impella CP with SmartAssist; Impella 5.0;

Cardiogenic Shock 104

Cardiogenic Shock Open-Heart Surgery Myocardial Infarction Heart Attack 104

DAIC

FEBRUARY 1, 2024

million, or 47% of adults are estimated to have hypertension.** Atherosclerosis Drugs Market Analysis In “Atherosclerosis Drugs Market Trend Analysis 2023 to 2033,” a market summary and forecasting report issued November 2023, FactMR reported several key findings. based on 2020 data used to compile AHA’s 2023 Statistical Update.

Cardiovascular Disease 104

Cardiovascular Disease Atherosclerosis Strokes Stroke 104

Hypertension Journal

SEPTEMBER 14, 2023

Hypertension, Volume 80, Issue 12 , Page 2533-2543, December 1, 2023. We examined contemporary trends in hypertension treatment and control in a national sample of adults with CKD.METHODS:We evaluated 5% cross-sectional samples of adults with CKD between 2011 and 2019 in the Veterans Health Administration.

Kidney Disease 40

Kidney Disease Hypertension Blood Pressure Outcomes 40

DAIC

MARCH 26, 2025

2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). 2023; Oct;29(10):1412-1451. Epub 2023 Sep 26. 4 Approximately 6.7 million adults in the U.S. 7 Of these patients, about 55% have a LVEF 40%. MPH, FACP, Vice President, US Medical Affairs, Bayer. J Card Fail.

Heart Failure 52

Heart Failure Preserved Ejection Fraction Kidney Disease ACE Inhibitor 52

Heart 2023 Conference

APRIL 20, 2022

JACC: Asia) Lexaria Bioscience has announced that a CBD product beats a placebo in simulating acute pulmonary hypertension.

Pulmonary 52

Pulmonary Hypertension AFIB COVID-19 52

DAIC

JUNE 19, 2024

While the spotlight in 2023 shone on developments around Generative Artificial Intelligence (AI), away from the limelight a quiet revolution in AI was taking place, which promises to transform the way we diagnose, manage, and treat cardiovascular diseases, the world’s leading cause of death.

AFIB 105

AFIB Reimbursement Research Atrial Fibrillation 105

Stroke: Vascular and Interventional Neurology

NOVEMBER 2, 2023

Stroke: Vascular and Interventional Neurology, Volume 3, Issue 6 , November 1, 2023. BackgroundIdiopathic intracranial hypertension (IIH) is prevalent among the US population, with exacerbation of symptoms during pregnancy. Transverse sinus stenting is a new effective treatment for IIH.

Stents 40

Stents Stent Hypertension Strokes 40

Circulation

OCTOBER 13, 2023

Circulation, Volume 148, Issue 24 , Page 1945-1957, December 12, 2023. BACKGROUND:Apparent treatment-resistant hypertension (aTRH) is prevalent and associated with adverse outcomes in heart failure with mildly reduced or preserved ejection fraction. per 100 patient-years in the nonresistant hypertension group, and 9.5

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Hypertension Myocardial Infarction 40

The American Journal of Cardiology

DECEMBER 31, 2023

Publication date: Available online 30 December 2023 Source: The American Journal of Cardiology Author(s): Tanmay Gokhale, Matthew E. Harinstein

Pulmonary 40

Pulmonary Hypertension 40

HCPLive

DECEMBER 14, 2023

Announced by Glaukos on December 14, 2023, the prostaglandin analog approval is indicated for the reduction of intraocular pressure among patients with ocular hypertension or open-angle glaucoma.

Hypertension 52

Hypertension 52

Dr. Paddy Barrett

JANUARY 2, 2024

Subscribe now 1 Hypertensive therapy: attacking the renin-angiotensin system. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. 2023 Aug 1;30(10):1017-1027. 2023 Aug 1;30(10):1017-1027. Presented at: AHA 2023. November 13, 2023. West J Med. 2001 Aug;175(2):119-24. N Engl J Med.

Blood Pressure 97

Blood Pressure Hypertension Heart Attack Heart attacks 97